PackGene to Showcase Scalable AAV Manufacturing, AI-Driven Capsid Engineering, and End-to-End CDMO Solutions at ASGCT 2025
Innovations in high-yield AAV production, in-process analytics, and targeted capsid design aim to make gene therapy affordable
Houston, TX – May 12, 2025 — PackGene Biotech, Inc. announced today six presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th annual meeting in New Orleans, May 13-17, highlighting the company’s comprehensive suite of innovative technology platforms and CDMO solutions designed to accelerate gene therapy development while lowering costs across the product lifecycle. From AI-assisted AAV capsid engineering to immunogenicity assays, from high-productivity vector manufacturing process improvement to robust process analytics tools, PackGene’s integrated approach aims to deliver end-to-end solutions from early-stage discovery research through product commercial launch.
“At PackGene, our mission is to make gene therapy affordable,” said Xin Swanson, Ph.D., Chief Strategy Officer, at PackGene. “We are excited to showcase our progress toward driving down gene therapy costs through innovation and tackling critical industry challenges, including vector tissue targeting, immunogenicity, safety, and manufacturability. Having successfully supported many programs from research through the clinic, we’re committed to working collaboratively with our academic and industry partners.”
Presentation Highlights
Tools and Technology Forum:
Title: Driving Down Costs: Advancing AAV Manufacturing for Affordable Gene Therapy
Time: May 16th, 2:00pm
Location: Exhibit Hall Presentation Theater
Poster Presentation:
Title: Advancing AAV Capsid Engineering for Targeted Gene Therapy Using PackGene’s π-Icosa Platform (AMA1046)-(916)
Time: May 13th, 6-7:30pm
Location: Poster Hall 2
Title: Enhancing AAV Production Efficiency through Plasmid Modification and Dual-Plasmid Systems (AMA1043)-(961)
Time: May 13th, 6-7:30pm
Location: Poster Hall 2
Title: Rationally designed chimeric AAV capsids demonstrate reduced liver tropism and enhanced muscle transduction in both rodents and non-human primates (AMA1049)-(1442)
Time: May 14th, 5-7:30pm
Location: Poster Hall 2
Title: Rapid and Accurate AAV Capsid Quantification Using Multi-Angle Dynamic Light Scattering (MADLS) for In-Process Gene Therapy Manufacturing (AMA1050)-(1480)
Time: May 14th, 5-7:30pm
Location: Poster Hall 2
Title: Evaluating Neutralizing Antibodies Against AAVs Using a High-Sensitivity LacZ Reporter Assay (AMA1053)-(1984)
Time: May 15th, 5-7:30pm
Location: Poster Hall 2
Poster presentation abstracts are publicly assessable through ASGCT website. PackGene will exhibit at booth 1821. For meeting requests or more information, please contact irene.song@packgene.com
Contacts:
PackGene Biotech Inc. , Corporate, Irene Song, Senior Director of Marketing, irene.song@packgene.com, 1-732-778-8546, https://www.packgene.com/
For media, Susan Thomas, Principal Endpoint Communications, susan@endpointcommunications.net, 1-619-540-9195
Source:
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
